logo
Thermo Fisher beats quarterly estimates on resilient demand for its tools and services

Thermo Fisher beats quarterly estimates on resilient demand for its tools and services

CTV News3 days ago
Sales at its laboratory products segment, which makes up more than half of Thermo Fisher's total sales came in at US$6 billion, above estimates of $5.79 billion.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment

Globe and Mail

time21 minutes ago

  • Globe and Mail

AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

Globe and Mail

time21 minutes ago

  • Globe and Mail

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.

AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics
AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics

Globe and Mail

timean hour ago

  • Globe and Mail

AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study titled 'A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours.' The study aims to assess how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, potentially offering new insights into cancer treatment. The intervention involves administering ceralasertib, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily over a week, with single doses of the other drugs administered on specific days to evaluate interactions. This open-label study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. It includes multiple visits and wash-out periods to ensure accurate results. The study began on May 21, 2025, with the latest update submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring transparency. For investors, this study could influence AstraZeneca's stock performance by potentially expanding its oncology portfolio. The collaboration with Parexel highlights a strategic partnership that could enhance research capabilities, impacting investor sentiment positively. Competitors in the oncology sector may also be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store